|
NIH trial shows promising results in treating a lymphoma in young people
National Institutes of Health (press release) Wyndham Wilson, M.D., Ph.D., head of NCI’s Lymphoma Therapeutics Section, and colleagues conducted the trial, in which every patient received the drugs etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab in a regimen … |
|
Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment …
Sacramento Bee The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled Phase 3 clinical trial, which compares PIXUVRI-rituximab to gemcitabine-rituximab in patients who … |
 ABC News |
Tamiflu sales boost Roche results despite efficacy concerns
PMLiVE … but there were solid gains for the firm’s blockbuster cancer drugs, with Herceptin (trastuzumab) and Avastin (bevacizumab) both rising 11 per cent to 1.57bn Swiss francs and 1.53bn Swiss francs respectively, and MabThera/Rituxan (rituximab) up 6 … Roche sales rise thanks to oncology drugs and TamifluPharmaTimes Roche 1st-qtr 2013 sales grow 6%, driven by cancer drugsThe Pharma Letter |
Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment …PR Newswire (press release)CTI is currently accruing patients into a Phase 3 trial comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell N…
Rituximab may obviate radiation in mediastinal B-cell lymphomaThe Oncology ReportPatients in a single-group, prospective phase II study were treated with dose-adjusted etoposide, doxorubicin, cyclophosphamide with vincristine, prednisone, and rituximab…
|
Rituxan Lymphoma Tx Works Without Radiation
MedPage Today A dose-adjusted, infusion approach to aggressive chemotherapy with rituximab (Rituxan) may allow patients with primary mediastinal B-cell lymphoma to skip radiation, a small uncontrolled trial suggested. Among 51 such treated patients, 97% survived and … New Strategy Helps Young Lymphoma Patients Avoid Radiation TreatmentU.S. News & World Report |
BioLineRx Receives Regulatory Approval to Commence Phase II Clinical Trial …PharmiWeb.com (press release)Pre-clinical studies show that BL-8040 is efficient both alone and in combination with the anti-cancer drug Rituximab in reducing bone marrow met…
|
Rituximab breder inzetbaar, ook in Europa
NierNieuws.nl In navolging van de Amerikaanse Food and Drug Administration (FDA) heeft nu ook de European Medicins Agency (EMA) besloten dat het medicijn Rituximab ingezet mag worden bij patiënten met twee vormen van auto-immuunvaatontstekingen die ook de … |
|
Is Chronic Fatigue Syndrome an Autoimmune Disease? – ProHealth
ProHealth In 2007 Øystein Fluge and Olav Mella, two Norwegian oncologists at Haukeland University Hospital in Bergen, Norway, accidentally discovered that rituximab, a drug employed to treat Hodgkin’s lymphoma (as well as autoimmune disorders such as … |
Unfolding the biosimilar landscape in Latin AmericaPMLiVEAn example of this is the early access by as the company Probiomed with their biosimilar rituximab, Kikuzubam, which was obtained just before this regulation was in place. By contrast, successful…